SCHEMBL12089998

SCHEMBL12089998

CC(C)(O)c1ccc(N2CCN(S(=O)(=O)c3cccs3)C[C@@H]2Cc2cccc(O)c2)cc1

nearest known ligand 0.81

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 14/20 0.81
GCK P35557 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12090131 1.00 GCKR (0.81) GCKRGCK
SCHEMBL12090143 1.00 GCKR (0.81) GCKRGCK
SCHEMBL12089564 0.91 GCKR (0.83) GCKRGCK
SCHEMBL12088966 0.91 GCKR (0.83) GCKRGCK
SCHEMBL12089655 0.91 GCKR (0.83) GCKRGCK
SCHEMBL12088937 0.91 GCKR (0.71) GCKRGCK
SCHEMBL12089087 0.91 GCKR (0.71) GCKRGCK
SCHEMBL12089389 0.91 GCKR (0.71) GCKRGCK
SCHEMBL12090124 0.90 GCKR (0.81) GCKRGCK
SCHEMBL12090122 0.90 GCKR (0.81) GCKRGCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCKR 1/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.